Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox (Mpox) Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Complement-targeted therapy for PNH
- Clinical burden of PNH
- PNH: issues in management
- Eculizumab: anti-C5 antibody
- Eculizumab can abrogate blood transfusions
- Eculizumab has an impact on the quality of life
- Eculizumab: targeted therapy for PNH
- Patterns of response to eculizumab in PNH
- C5 blockade is associated with C3-binding
- Mechanism of (iatrogenic) hemolysis in PNH
- 2 modalities of sub-optimal eculizumab response
- The structure of C5 and inhibiting C5 cleavage
- The response to eculizumab is influenced by CR1
- Eculizumab and splenic artery embolization
- Summary on sub-optimal response to eculizumab
- Eculizumab: targeted therapy for PNH
- Eculizumab alleviates the clinical burden of PNH
- Outstanding problems with eculizumab (anti-C5)
- Anaemias due to intravascular hemolysis
- PNH (recap)
- There are two major forms of PNH
- Bone marrow failure and PNH
- Somatic mutations in PNH: a blessing in disguise
- Pathogenesis of PNH
- Complement–targeted therapy: new developments
- Complexity of complement & new targets
- Acknowledgements
Topics Covered
- Complement-targeted therapy for PNH
- Mechanism of (iatrogenic) hemolysis in PNH
- Pathogenesis of PNH
- Anaemias due to intravascular hemolysis
- Bone marrow failure and PNH
- Somatic mutations in PNH
- Clinical burden of PNH
- PNH: issues in management
- Eculizumab (anti-C5 Ab): targeted therapy for PNH
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Luzzatto, L. (2017, June 29). Complement in PNH and other hemolytic anaemias 3 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 23, 2024, from https://doi.org/10.69645/OOLT2885.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Lucio Luzzatto has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Complement in PNH and other hemolytic anaemias 3
Published on June 29, 2017
27 min
Other Talks in the Series: The Complement System
Transcript
Please wait while the transcript is being prepared...
0:00
This is part three of my talk.
My name is Lucio Luzzatto,
I'm a hematologist at
the Muhimbili University of Health and Applied Sciences in Dar-es-Salaam, Tanzania.
0:14
The notion that by blocking complement,
you could avoid hemolysis PNH is not a new concept.
But of course we didn't have the technology until
the technology of monoclonal antibodies was introduced.
So, can we take advantage of this to treat these patients?
0:40
So this for a hematologist,
are the very many aspects of the clinical burden of PNH.
Not only there is anemia,
but there is risk of thrombosis,
there is the risk of
annal depletion through into intravascular hemolysis causing abdominal pain.
It can also cause dysphagia, pulmonary hypertension,
erectile dysfunction, and multiple problems in pregnancy.
So, many of these are complicated in an indirect way,
but they all stem from the basic process which I have illustrated.
1:19
Until recently, the treatment of PNH
was based on support of the patient including blood transfusion,
possible radical treatment through
bone marrow transplantation, and sometimes immunosuppression.
I cannot go now into how that works.
Also, we needed anticoagulant prophylaxis to prevent
thrombosis and various procedure in pregnancy.